» Articles » PMID: 2442630

Evidence for Inhibition by ICS 205-930 and Stimulation by BRL 34915 of K+ Conductance in Cardiac Muscle

Overview
Specialty Pharmacology
Date 1987 Jun 1
PMID 2442630
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Electrophysiological effects of the 5-HT3 receptor antagonist ICS 205-930 [(3 alpha-tropanyl)-1H-indole-3-carboxylic acid ester] were investigated in guinea pig isolated heart preparations. ICS 205-930 prolonged the functional refractory period and decreased the force of contraction in left driven atria. It decreased spontaneous beating rate in right atria. These effects were concentration dependent between 3 X 10(-6) and 10(-4) mol/l of ICS 205-930. In fast action potentials of papillary muscles ICS 205-930 concentration-dependently depressed Vmax and prolonged the action potential duration (APD) between 10(-6) and 10(-5) mol/l. The action potential amplitude (APA) and the resting membrane potential (RMP) remained unchanged. In papillary muscles partially depolarized by high K+ (22 mmol/l) and reactivated by high voltage stimulation, slow response APs were prolonged by ICS 205-930 10(-6) to 3 X 10(-5) mol. Vmax, APA and RMP were not affected. Similar effects on APD were obtained with sotalol (3 X 10(-5) mol/l), an inhibitor of outward K+ current. The slow-APD prolongation induced by ICS 205-930 as well as by sotalol was reversed by BRL 34915 (6-cyano-3,4-dihydro-2,2-dimethyltrans-4-(2-oxo-1-pyrrolidyl )-2H-benzo[b]pyran-3-ol), known to open K+ channels. BRL 34915 alone reduced slow-APD stereoselectively. The results suggest that ICS 205-930 may inhibit and BRL 34915 may stimulate the K+ conductance of guinea pig myocardial cell membranes.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

The effects of SB 204070, a highly potent and selective 5-HT4 receptor antagonist, on guinea-pig distal colon.

Wardle K, Ellis E, Baxter G, Kennett G, Gaster L, Sanger G Br J Pharmacol. 1994; 112(3):789-94.

PMID: 7921604 PMC: 1910219. DOI: 10.1111/j.1476-5381.1994.tb13148.x.


Block of the delayed rectifier current (IK) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes.

de Lorenzi F, Bridal T, Spinelli W Br J Pharmacol. 1994; 113(2):527-35.

PMID: 7834204 PMC: 1510143. DOI: 10.1111/j.1476-5381.1994.tb17021.x.


The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle.

Yanagisawa T, Hashimoto H, Taira N Br J Pharmacol. 1988; 95(2):393-8.

PMID: 2852521 PMC: 1854162. DOI: 10.1111/j.1476-5381.1988.tb11658.x.


Phentolamine and structurally related compounds selectively antagonize the vascular actions of the K+ channel opener, cromromakalim.

McPherson G, Angus J Br J Pharmacol. 1989; 97(3):941-9.

PMID: 2758244 PMC: 1854571. DOI: 10.1111/j.1476-5381.1989.tb12035.x.


Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT3 receptor antagonist ICS 205-930.

Berthold H, Scholtysik G, Engel G Naunyn Schmiedebergs Arch Pharmacol. 1989; 339(3):259-62.

PMID: 2725703 DOI: 10.1007/BF00173574.


References
1.
Singh B, VAUGHAN WILLIAMS E . The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970; 39(4):657-67. PMC: 1702721. DOI: 10.1111/j.1476-5381.1970.tb09891.x. View

2.
Reuter H . Properties of two inward membrane currents in the heart. Annu Rev Physiol. 1979; 41:413-24. DOI: 10.1146/annurev.ph.41.030179.002213. View

3.
Strauss H, BIGGER Jr J, Hoffman B . Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res. 1970; 26(6):661-78. DOI: 10.1161/01.res.26.6.661. View

4.
BACANER M, CLAY J, Shrier A, Brochu R . Potassium channel blockade: A mechanism for suppressing ventricular fibrillation. Proc Natl Acad Sci U S A. 1986; 83(7):2223-7. PMC: 323264. DOI: 10.1073/pnas.83.7.2223. View

5.
Lynch J, Wilber D, Montgomery D, Hsieh T, Patterson E, Lucchesi B . Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol. J Cardiovasc Pharmacol. 1984; 6(6):1132-41. View